|Systematic (IUPAC) name|
1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
|ATC code||J05AF12 (WHO) |
|Molar mass||260.219 g/mol|
|(what is this?)|
Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.
Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. Its approval in South Korea was revoked following these findings. Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use. 
- WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
- Tak WY, Yang JM, Kim BI, Baik SK, Cheon GJ, Byun KS, Kim DY, Yoo BC, et al. (May 2014). "A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.". Hepatology International 8 (3): 375–381. doi:10.1007/s12072-014-9537-5. PMID 25101150.
- Lee HS, Chung YH, Lee K, et al. (May 2006). "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B". Hepatology 43 (5): 982–8. doi:10.1002/hep.21166. PMID 16628625.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|